tenascin CGenealiases: 150-225 · DFNA56 · GMEM · GP · HXB · JI
Q-omics provides the consensus-scored TNC profile across patient tissues and cancer cell-line models. TNC expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TNC is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, TNC RNA expression shows 18,002 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, HNSC, and DLBC as cancer lineages where TNC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNC survival associations across molecular data types. TNC RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNC RNA expression–survival associations across cancer types. High TNC expression shows unfavorable associations in BLCA, MESO, LGG, UVM and ACC, but favorable associations in ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TNC RNA expression.
This table summarizes TNC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TNC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNC shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, THCA, LUAD and LUSC. The HNSC box plot shows higher TNC RNA expression in tumor versus normal tissue (log2 FC = +3.313, t-test p < 0.001).
This table shows molecular features associated with TNC in patient tissues and cancer cell lines. In patient samples, TNC shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
